Merck KGaA Plays Down Mavenclad Label And $99,500 annual Price For 10 MS Pills
Merck KGaA's multiple sclerosis pill Mavenclad has finally won FDA approval, but some analysts think its US label, stipulating second-line use in relapsing MS but not in patients with clinically isolated syndrome, may hurt its uptake there.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide in 2019 if all goes well across the Atlantic.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.